Welcome to our dedicated page for Omnicell Com SEC filings (Ticker: OMCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omnicell, Inc. (NASDAQ: OMCL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. As a publicly traded healthcare technology company focused on intelligent medication management, Omnicell files a range of reports with the U.S. Securities and Exchange Commission that describe its financial condition, risks, governance, and material events.
Investors and researchers can use this page to review Omnicell’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss topics such as revenues from connected devices, technical services, SaaS and Expert Services, and consumables, as well as the company’s strategy to transform into a digitally enabled medication management technology company. Current reports on Form 8-K provide timely updates on matters including quarterly financial results, amendments to bylaws, and the appointment of executive officers.
For users interested in governance and corporate structure, filings detail actions like the adoption of amended and restated bylaws that refine stockholder nomination procedures, address proxy rule requirements, and clarify jurisdictional provisions. Risk factor discussions in Omnicell’s periodic reports outline considerations related to economic conditions, demand for medication management solutions, regulatory and legal obligations, cybersecurity, supply chain, and competition.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the implications of Omnicell’s 10-Ks, 10-Qs, and 8-Ks without reading every page. Real-time updates from EDGAR, combined with structured access to historical filings, allow investors to follow how OMCL’s disclosures evolve over time and to connect regulatory information with the company’s broader narrative in medication management technology.
Njoku Nnamdi reported acquisition or exercise transactions in this Form 4 filing.
OMNICELL, INC. Executive Vice President and Chief Operating Officer Nnamdi Njoku received a grant of 46,296 shares of common stock in the form of Restricted Stock Units as equity compensation. The award was granted under the company’s equity incentive plan at no cash cost to him.
One-third of these RSUs will vest on the first anniversary of the April 1, 2026 grant date. The remaining two-thirds will vest in equal installments on the second and third anniversaries. After this grant, Njoku directly holds 161,535.4457 shares of Omnicell common stock.
Manley Corey J reported acquisition or exercise transactions in this Form 4 filing.
OMNICELL, INC. executive Corey J. Manley, EVP & Chief Legal/Admin Officer, received a grant of 25,132 Restricted Stock Units (RSUs) of common stock at a stated price of $0.00 per share, reflecting a compensation-related equity award rather than a market purchase.
According to the award terms, one-third of the RSUs will vest on the first anniversary of the grant date, with the remaining two-thirds vesting in equal installments on the second and third anniversaries. Following this grant, Manley directly holds a total of 121,849.3392 shares of Omnicell common stock, including this new RSU award.
LIPPS RANDALL A reported acquisition or exercise transactions in this Form 4 filing.
OMNICELL, INC. Chairman, President and CEO Randall A. Lipps received a grant of 90,939 shares of Common Stock in the form of restricted stock units at a price of $0.00 per share on 2026-04-01. These RSUs were granted under the company’s equity incentive plan.
According to the vesting schedule, one-third of the RSUs will vest on the first anniversary of the grant date, with the remaining two-thirds vesting in equal installments on the second and third anniversaries. After this grant, Lipps directly holds 535,531.0741 shares of Common Stock.
In addition to his direct holdings, shares are also held indirectly in trusts: 355,861 shares are held in trust with his wife, and 8,051 shares are held in trust for the benefit of his children.
Radford Harlan Baird reported acquisition or exercise transactions in this Form 4 filing.
OMNICELL, INC. reported that EVP & Chief Financial Officer Harlan Baird Radford received a grant of 37,037 shares of Common Stock in the form of Restricted Stock Units under the company’s equity incentive plan. One-third of the RSUs will vest on the first anniversary of the grant date, with the remaining two-thirds vesting in equal installments on the second and third anniversaries. Following this award, Radford directly holds 69,969 shares of Common Stock.
NUTT BRIAN H. reported acquisition or exercise transactions in this Form 4 filing.
OMNICELL, INC. reported that VP and Chief Accounting Officer Brian H. Nutt received a grant of 5,556 shares of common stock in the form of Restricted Stock Units under the company’s equity incentive plan. These RSUs were awarded at no cash cost per share and increase his directly held position to 23,085.6135 shares.
According to the award terms, one-third of the RSUs will vest on the first anniversary of the grant date, and the remaining two-thirds will vest in equal installments on the second and third anniversaries. This structure is typical for long-term incentive compensation designed to retain executives over multiple years.
Omnicell, Inc. Schedule 13G discloses that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared beneficial ownership of 2,288,570 shares of Omnicell common stock, representing 5.0% of the class. The filing is a joint filing and is signed by the reporting parties.
The filing states the shares are held by entities over which reporting persons have voting and investment discretion and provides the reporting persons' addresses and citizenships. Exhibit I is a Joint Filing Agreement dated March 31, 2026.
The Vanguard Group filed an amendment to its Schedule 13G/A reporting 0% beneficial ownership of Omnicell Inc. common stock. The filing states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries and business divisions will report holdings separately in reliance on SEC Release No. 34-39538. The amendment, signed on March 27, 2026, lists 0 shares beneficially owned and 0% of the class, with no sole or shared voting or dispositive power.
Omnicell, Inc. Chairman, President and CEO Randall A. Lipps reported vesting of 79,494 performance-based restricted stock units of Common Stock. These RSUs were originally granted on March 15, 2025 and became earned after the company met stock performance objectives versus the S&P 1000 Healthcare Index, with 25% vesting on the one-year anniversary of the grant.
In connection with this vesting, 15,642 shares were withheld at $34.40 per share to cover tax liabilities, leaving 444,592 Common Stock shares held directly after the transactions. Separate from his direct holdings, 355,861 shares are held in a trust with his wife and 8,051 shares are held in a trust for his children.
Omnicell EVP and COO Nnamdi Njoku reported equity compensation changes tied to performance-based restricted stock units. He acquired 37,409 common shares at no cost upon vesting of previously granted performance-based RSUs after the company met stock performance objectives versus the S&P 1000 Healthcare Index.
Of these vested shares, 8,456 were withheld to cover taxes at a price of $34.40 per share. Following these transactions, Njoku directly holds 115,239.4457 shares of Omnicell common stock. The remaining performance-based RSUs will vest in equal quarterly installments over three years.
Omnicell EVP and Chief Legal/Admin Officer Corey J. Manley reported equity compensation vesting and related share transactions. On March 15, 2026, he acquired 22,445 shares of Common Stock at $0.00 per share as a grant tied to performance-based restricted stock units previously awarded on March 15, 2025.
On the same date, 3,819 shares were withheld at $34.40 per share to cover taxes due upon vesting of these restricted stock units. On March 16, 2026, he sold 7,405 shares in an open-market transaction at an exact price of $34.69 per share under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2025.
Following these transactions, Manley directly held 96,717.3392 shares of Omnicell Common Stock. The remaining performance-based restricted stock units from the March 2025 grant will vest in equal quarterly increments every three months over a three-year period, on each May 15, August 15, November 15, and February 15.